We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis.
- Authors
Agarwal, Amil R.; Kinnard, Matthew J.; Murdock, Christopher; Zhao, Amy Y.; Ahiarakwe, Uzoma; Cohen, Jordan S.; Moseley, Kendall F.; Golladay, Gregory J.; Thakkar, Savyasachi C.
- Abstract
Summary: Osteoporosis treatment following arthroplasty for femoral neck fracture (FNF) is associated with lower rates of periprosthetic fracture (PPF). Our study evaluated the economic viability of treatment in patients following arthroplasty and demonstrates that treatment with oral bisphosphonates can be cost-effective in preventing PPF. Introduction: Osteoporosis treatment following arthroplasty for femoral neck fracture (FNF) is associated with lower rates of periprosthetic fracture (PPF). Although cost-effective in reducing the rate of secondary fragility fracture, the economic viability of osteoporosis treatment in preventing PPF has not been evaluated. Therefore, the purpose of this study is to use a break-even analysis to determine whether and which current osteoporosis medications are cost-effective in preventing PPF following arthroplasty for FNFs. Methods: Three-year average cost of osteoporosis medication (oral bisphosphonates, estrogen hormonal therapy, intravenous (IV) bisphosphonates, denosumab, teriparatide, and abaloparatide), costs of PPF care, and PPF rates in patients who underwent hip arthroplasty for FNFs without osteoporosis treatment were used to perform a break-even analysis. The absolute risk reduction (ARR) related to osteoporosis treatment and sensitivity analyses were used to evaluate the cost-effectiveness of this intervention and break-even PPF rates. Results: Oral bisphosphonate therapy following arthroplasty for hip fractures would be economically justified if it prevents one out of 56 PPFs (ARR, 1.8%). Given the current cost and incidence of PPF, overall treatment can only be economically viable for PPF prophylaxis if the 3-year costs of these agents are less than $1500. Conclusion: The utilization of lower cost osteoporosis medications such as oral bisphosphonates and estrogen hormonal therapy as PPF prophylaxis in this patient population would be economically viable if they reduce the PPF rate by 1.8% and 1.5%, respectively. For IV bisphosphonates and newer agents to be economically viable as PPF prophylaxis in the USA, their costs need to be significantly reduced.
- Subjects
COST control; COST effectiveness; TOTAL hip replacement; DIPHOSPHONATES; TERIPARATIDE; DRUG therapy; COST analysis; SAMPLE size (Statistics); ESTROGEN; PEPTIDE hormones; DESCRIPTIVE statistics; MONOCLONAL antibodies; FEMORAL neck fractures; HORMONE therapy; OSTEOPOROSIS; PERIPROSTHETIC fractures
- Publication
Osteoporosis International, 2024, Vol 35, Issue 7, p1223
- ISSN
0937-941X
- Publication type
Article
- DOI
10.1007/s00198-024-07085-6